Form 4: Revolution Medicines CEO Mark Goldsmith Executes Stock Option and Sells Shares Under 10b5-1 Plan

Mark Goldsmith, CEO of Revolution Medicines, exercised stock options and sold shares of common stock under a pre-arranged 10b5-1 trading plan.

Summary

• On July 12, 2024, Mark A. Goldsmith, the President and CEO of Revolution Medicines, exercised stock options to acquire 25,000 shares of common stock at a price of $4.09 per share.
• Simultaneously, Goldsmith sold 25,000 shares at a weighted average price of $45.0482 and 5,000 shares at a weighted average price of $45.0116 and 5,000 shares at a weighted average price of $45.0118.
• These transactions were executed under a 10b5-1 trading plan adopted on December 1, 2023.
• Following these transactions, Goldsmith directly owns 311,885 shares of common stock and indirectly owns 25,424 shares through the Jonathan Goldsmith Revocable Trust, 25,424 shares through the Rebecca Eve Goldsmith Trust, and 465,604 shares through the Mark A. Goldsmith and Anne E. Midler 2002 Revocable Living Trust.

Sentiment

Score: 6

Explanation: The sentiment is neutral. The filing simply reports stock transactions under a pre-existing plan. There's no inherent positive or negative signal.

Positives

• The transactions were executed under a pre-arranged 10b5-1 trading plan, which can mitigate concerns about insider trading.

Risks

• Executive stock sales can sometimes be perceived negatively by investors, although the 10b5-1 plan mitigates this concern.

Industry Context

Executive stock transactions are common in publicly traded companies, and the use of 10b5-1 plans is a standard practice to avoid insider trading concerns. The pharmaceutical industry is closely watched for insider trading due to the potential for significant stock price movements based on clinical trial results and regulatory approvals.

Comparison to Industry Standards

• Executive compensation packages in the pharmaceutical industry often include stock options and restricted stock units to align management's interests with those of shareholders.
• The use of 10b5-1 trading plans is a common practice among executives in publicly traded companies, including those in the pharmaceutical sector, such as Pfizer, Amgen, and Johnson & Johnson, to manage their personal finances while avoiding accusations of insider trading.
• The size and frequency of stock sales by executives can vary widely depending on their individual financial circumstances and the company's stock performance.

Stakeholder Impact

• The stock sales could have a minor impact on shareholders, but the 10b5-1 plan mitigates concerns about insider trading.

Key Dates